A practical reference on lyophilization: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-02-07 and is reviewed periodically as new material appears.
Published information places retatrutide in clinical development rather than on the market as an approved therapy. Early-stage and mid-stage trials have examined tolerability and changes in body weight, and larger studies continue to report results over time. Open questions include the durability of effects after treatment stops, the composition of weight lost, and cardiovascular outcomes over long periods. Statements about definitive benefit should therefore be treated as provisional. Regulatory status varies by jurisdiction and changes as applications are reviewed.
Retatrutide is an investigational synthetic peptide designed to activate three distinct receptor systems within a single molecule. Its pharmacological profile combines activity at the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This arrangement places it within a broader class of agents often described as multi-agonists, which contrast with compounds that engage one or two targets. Research interest centers on whether simultaneous signaling produces effects that single-receptor agonists cannot achieve alone. A single molecular entity also simplifies manufacturing and delivery logistics compared with combining separate agents.
Mechanistic proposals link each receptor to a different physiological role. Activation of the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors is associated with reduced appetite, slower gastric emptying, and glucose-dependent insulin release. Glucagon receptor signaling, by contrast, is associated with increased energy expenditure and altered lipid handling, though it can also raise blood glucose. The design intent is to balance these contributions so that weight reduction is enhanced without unacceptable glycemic trade-offs. How well that balance holds across individuals is not fully resolved.
该分子是经过结构修饰的合成肽，通过脂肪酸侧链与白蛋白结合，从而延长循环时间。皮下给药后，药物逐步释放并分布至组织。降解主要依赖蛋白酶，肾脏清除占次要地位。人体半衰期以天为单位，但准确数值随检测方法和个体差异而变；组织分布与受体占有率仍是开放问题。
临床研究通常测量体重、腰围、空腹血糖、糖化血红蛋白和血脂，并记录不良事件。药代动力学评估关注浓度-时间曲线，药效动力学评估关注代谢标志物变化。体重下降由能量摄入减少、能量消耗变化和脂肪组织重塑共同造成，具体权重仍不明确。研究之间的终点定义和随访时长差异使横向比较复杂。
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Studied for metabolic indications |
| Receptor activity | GIP, GLP-1, and glucagon | Single molecule, three targets |
| Development status | Investigational | Not an approved therapy |
| Common synonym | LY3437943 | Development designation |
| Administration route | Subcutaneous injection | As used in clinical studies |
与仅靶向单一受体的同类药物相比，瑞他鲁肽增加胰高血糖素受体成分，理论上可提高能量消耗并改变脂肪分布。临床中观察到的体重变化是否主要来自该额外机制，目前尚无定论。胃肠道反应是该类药物常见不良事件，试验中通过剂量递增和监测进行管理。停药后体重反弹、个体差异和长期耐受性仍需更多数据。
瑞他鲁肽是一种在研合成肽，同时作用于胰高血糖素样肽-1、葡萄糖依赖性促胰岛素多肽和胰高血糖素受体。该分子属于多受体激动剂类别，尚未获得任何监管机构的上市批准。当前临床开发主要针对肥胖和2型糖尿病，研究代号为LY3437943。已确立的信息包括受体靶点和部分中期试验结果；最终疗效、长期安全性和适用人群仍属开放问题。
Solid material is generally held at -20 °C or colder, while reconstituted solutions are kept at 2-8 °C and used within a short window. Buffers that maintain a slightly acidic to neutral pH tend to improve short-term peptide stability. Repeated warming and cooling of stock solutions promotes aggregation and should be avoided. Container closures should remain intact, since adsorption to some plastics can reduce the amount of peptide in solution.
Identity and purity are established with reversed-phase high-performance liquid chromatography and mass spectrometry. Chromatographic profiles reveal related impurities, truncated sequences, and oxidation products, while mass measurement confirms the expected molecular mass. Purity values for research material are typically reported as a percentage by peak area. Reference standards help calibrate retention behavior across instruments. Independent laboratories emphasize method suitability because results depend heavily on column chemistry, gradient, and detection wavelength. Batch-to-batch comparison relies on the same validated method.
== History == Avasimibe was the result of a rational drug design process carried out at Parke-Davis in the early 1990s which sought to obtain orally bioavailable, water-soluble ACAT inhibitors; all such inhibitors known at the time were lipophilic and poorly absorbed when taken by mouth. This process yielded several compounds with potential, including one (designated PD 138142–15) with good solubility in water and remarkable efficacy in animal studies, but it was chemically unstable and degraded rapidly, especially in acidic environments. (Undesirable CYP450 induction was first noted at this time, in PD 138142-15 and its degradation products.) Chemical modification of PD 138142-15 and retrosynthetic analysis found that avasimibe (then codenamed CI-1011) could be easily manufactured from commercially available starting compounds, and once its efficacy was demonstrated in vitro and in rat studies, it was selected for further development. After additional safety and preclinical efficacy studies in animals, phase I clinical trials in humans began in 1997, first for hyperlipidemia (June) and subsequently for atherosclerosis (December). Phase II trials for both indications followed in 1998, and phase III trials in 2001. In October 2003, clinical development of avasimibe was discontinued. Later research discredited the concept of ACAT inhibition as a treatment for dyslipidemia and atherosclerosis, and interest in these compounds as a class waned accordingly.
== History == An early report on indigo-blue pigment-producing bacteria was published by Heinr Claessen in 1890, describing a Bacillus isolated from water that produced an indigo-blue dye. Otto Voges researched and described the bacterial species Bacillus indigoferus in 1893, renamed after him to Vogesella indigofera, in Kiel, which continuously discolored the surrounding medium (water) from slightly bluish (24 hours) to royal blue (48 hours). In 1964 and 1965, Nobel laureate Richard Kuhn and his colleagues published several articles in the scientific press on the occurrence, structure and synthesis of indigoidine. In 1979, Carl-Gerd Dieris and H.-D. Scharf described another synthesis of the compound.
Nevertheless, despite their technical prowess, Japan chose to use its submarines for fleet warfare, and consequently were relatively unsuccessful, as warships were fast, maneuverable and well-defended compared to merchant ships. The submarine force was the most effective anti-ship weapon in the American arsenal. Submarines, though only about 2 percent of the U.S. Navy, destroyed over 30 percent of the Japanese Navy, including 8 aircraft carriers, 1 battleship and 11 cruisers. US submarines also destroyed over 60 percent of the Japanese merchant fleet, crippling Japan's ability to supply its military forces and industrial war effort. Allied submarines in the Pacific War destroyed more Japanese shipping than all other weapons combined. This feat was considerably aided by the Imperial Japanese Navy's failure to provide adequate escort forces for the nation's merchant fleet. During World War II, 314 submarines served in the US Navy, of which nearly 260 were deployed to the Pacific. When the Japanese attacked Hawaii in December 1941, 111 boats were in commission; 203 submarines from the Gato, Balao, and Tench classes were commissioned during the war. During the war, 52 US submarines were lost to all causes, with 48 directly due to hostilities. US submarines sank 1,560 enemy vessels, a total tonnage of 5.3 million tons (55% of the total sunk). The Royal Navy Submarine Service was used primarily in the classic Axis blockade. Its major operating areas were around Norway, in the Mediterranean (against the Axis supply routes to North Africa), and in the Far East.
The most common application of cervical drug delivery is for treatment of cervical cancer. Due to the direct route provided through the use of cervical drug delivery mechanisms, it proves to be the most effective route with the lowest number of side effects. The localized treatment has been suggested as ideal as cancer is treated with highly toxic compounds, such as chemotherapeutics. The more contained the exposure to these compounds can be, the less negative impacts the patient will endure. Treatment can be delivered in the form of nanoparticles, vaginal gels, or films and reach the cervix quickly for ideal response. Vaginal gels are easily administered into the vaginal canal to reach the cervix due to low viscosity at room temperature. When inserted into the body which has a higher temperature, the gels become more viscous, allowing them to reside longer at the cervix and have more sustained release. Vaginal films are very thin films inserted into the vagina to release a compound. They can be maintained for six hours in cervical mucus, meaning they hold potential to treat cervical cancer caused by Human Papilloma Virus. Nanoparticle systems take advantage of the size of nanoparticles to encapsulate the drugs and pass through the mucus barrier.
Sources: en.wikipedia.org
It has hitherto been necessary to postulate some special arbitrary "instability" of the nucleus, but in the following note, it is pointed out that disintegration is a natural consequence of the laws of quantum mechanics without any special hypothesis... Much has been written of the explosive violence with which the α-particle is hurled from its place in the nucleus. But from the process pictured above, one would rather say that the α-particle almost slips away unnoticed. The theory supposes that the alpha particle can be considered an independent particle within a nucleus, that is in constant motion but held within the nucleus by strong interaction. At each collision with the repulsive potential barrier of the electromagnetic force, there is a small non-zero probability that it will tunnel its way out. An alpha particle with a speed of 1.5×107 m/s within a nuclear diameter of approximately 10−14 m will collide with the barrier more than 1021 times per second. However, if the probability of escape at each collision is very small, the half-life of the radioisotope will be very long, since it is the time required for the total probability of escape to reach 50%. As an extreme example, the half-life of the isotope bismuth-209 is 2.01×1019 years. The isotopes in beta-decay stable isobars that are also stable with regards to double beta decay with mass number A = 5, A = 8, 143 ≤ A ≤ 155, 160 ≤ A ≤ 162, and A ≥ 165 are theorized to undergo alpha decay. All other mass numbers (isobars) have exactly one theoretically stable nuclide.
== Food and beverage use == S. boulardii is usable in beer brewing, with live yeast remaining in the finished product. It can coexist alongside other S. cerevisiae in mixed starter cultures. It can also be used for baking, where its ability to deter bacteria translates into inhibition of rope spoilage, a bread defect caused by Bacillus subtilis or Bacillus licheniformis contamination.
== Diagnosis == No specific test exists to diagnose polymyalgia rheumatica; many other diseases can cause inflammation and pain in muscles, but a few tests can help narrow down the cause of the pain. Limitation in shoulder motion or swelling of the joints in the wrists or hands, are noted by the doctor. One blood test usually performed is the erythrocyte sedimentation rate (ESR) which measures how fast the patient's red blood cells settle in a test tube. The faster the red blood cells settle, the higher the ESR value (measured in mm/hour), which suggests that inflammation may be present. Many conditions can cause an elevated ESR, so this test alone is not proof that a person has polymyalgia rheumatica. Another test that checks the level of C-reactive protein (CRP) in the blood may also be conducted. CRP is produced by the liver in response to an injury or infection, and people with polymyalgia rheumatica usually have high levels. However, like the ESR, this test is also not very specific. Polymyalgia rheumatica is sometimes associated with temporal arteritis, a condition requiring more aggressive therapy. To test for this additional disorder, a biopsy sample may be taken from the temporal artery.
A cocurrent heat exchanger is an example of a cocurrent flow exchange mechanism. Two tubes have a liquid flowing in the same direction. One starts off hot at 60 °C (140 °F), the second cold at 20 °C (68 °F). A thermoconductive membrane or an open section allows heat transfer between the two flows. The hot fluid heats the cold one, and the cold fluid cools down the warm one. The result is thermal equilibrium: Both fluids end up at around the same temperature: 40 °C (104 °F), almost exactly between the two original temperatures (20 °C (68 °F) and 60 °C (140 °F)). At the input end, there is a large temperature difference of 40 °C (104 °F) and much heat transfer; at the output end, there is a very small temperature difference (both are at the same temperature of 40 °C (104 °F) or close to it), and very little heat transfer if any at all. If the equilibrium—where both tubes are at the same temperature—is reached before the exit of the liquid from the tubes, no further heat transfer will be achieved along the remaining length of the tubes. A similar example is the cocurrent concentration exchange. The system consists of two tubes, one with brine (concentrated saltwater), the other with freshwater (which has a low concentration of salt in it), and a semi permeable membrane which allows only water to pass between the two, in an osmotic process. Many of the water molecules pass from the freshwater flow in order to dilute the brine, while the concentration of salt in the freshwater constantly grows (since the salt is not leaving this flow, while water is).
== Nomenclature == In addition to the IUPAC numbering system to differentiate the various carbons in an organic molecule, by sequentially assigning a number to each carbon, including those forming a carboxylic group, the carbons along the side-chain of amino acids can also be labelled with Greek letters, where the α-carbon is the central chiral carbon possessing a carboxyl group, a side chain and, in α-amino acids, an amino group – the carbon in carboxylic groups is not counted. (Consequently, the IUPAC names of many non-proteinogenic α-amino acids start with 2-amino- and end in -ic acid.)
Sources: en.wikipedia.org
I hated authority like hell." From 1964 to 1965, Biko studied at St. Francis College, a Catholic boarding school in Mariannhill, Natal. The college had a liberal political culture, and Biko developed his political consciousness there. He became particularly interested in the replacement of South Africa's white minority government with an administration that represented the country's black majority. Among the anti-colonialist leaders who became Biko's heroes at this time were Algeria's Ahmed Ben Bella and Kenya's Jaramogi Oginga Odinga. He later said that most of the "politicos" in his family were sympathetic to the PAC, which had anti-communist and African racialist ideas. Biko admired what he described as the PAC's "terribly good organisation" and the courage of many of its members, but he remained unconvinced by its racially exclusionary approach, believing that members of all racial groups should unite against the government. In December 1964, he travelled to Zwelitsha for the ulwaluko circumcision ceremony, symbolically marking his transition from boyhood to manhood.
==== Distribution ==== The drug is distributed widely throughout the body, including in saliva, bile, cerebrospinal fluid, synovial fluids, and pleural effusions. In accordance with its presence in cerebrospinal fluid, methenamine is known to cross the blood–brain barrier and enter the central nervous system. The volume of distribution and plasma protein binding of methenamine are unknown.
These emotions occur in both bottle- and breast-feeding mothers, although for different reasons. Bottle-feeding mothers may feel they should be breastfeeding. Conversely, breastfeeding mothers may feel forced to feed in uncomfortable circumstances. Some may see breastfeeding as "indecent, disgusting, animalistic, sexual, and even possibly a perverse act." Advocates (known by the neologism "lactivists") use "nurse-ins" to show support for breastfeeding in public. One study that approached the subject from a feminist viewpoint suggested that both nursing and non-nursing mothers often feel maternal guilt and shame, with formula-feeding mothers feeling that they are not living up to the ideals of motherhood and nursing mothers concerned that they are transgressing "cultural expectations regarding feminine modesty." The authors advocate that women be provided with education on breastfeeding's benefits as well as problem-solving skills, however, there is no conclusive evidence that breastfeeding education alone improves initiation of breastfeeding or the proportion of women breastfeeding either exclusively or partially at 3 months and 6 months.
=== Sources to people === Food, drinking water, outdoor air, indoor air, dust, and food packagings are all implicated as sources of PFOA to people. However, it is unclear which exposure routes dominate because of data gaps. When water is a source, blood levels are approximately 100 times higher than drinking water levels. People who lived in the PFOA-contaminated area around DuPont's Washington Works facility were found to have higher levels of PFOA in their blood from drinking water. The highest PFOA levels in drinking water were found in the Little Hocking water system, with an average concentration of 3.55 parts per billion during 2002–2005. Individuals who drank more tap water, ate locally grown fruits and vegetables, or ate local meat, were all associated with having higher PFOA levels. Residents who used water carbon filter systems had lower PFOA levels. In Jersey, UK, 18% of residents of an area were found to have elevated levels of PFOA, downstream from 3M fire retardant tests in weekly fire-service practice from the 1960s to the mid 1990s. Bloodletting is used for these residents at a cost of $4500 per patient. The potatoes of the island were found to contain 10x the EU limit of PFOS.
Sources: en.wikipedia.org
It is described as a single molecule that acts at three receptors: the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This triple activity distinguishes it from agents that target one or two of these pathways.
It is characterized in the literature as an investigational agent under clinical study. Approval status depends on jurisdiction, and readers should check current regulatory information rather than assume availability.
The combination is intended to pair appetite-related and glucose-related effects with mechanisms that increase energy expenditure. Whether the combined profile offers advantages over simpler agonists is the subject of ongoing research.
意味着单个分子可同时结合三种代谢受体，而不是只作用于一种。其目的是整合食欲、胰岛素和能量消耗通路，但人体中的协同程度仍在研究。